My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

MaxCyte, Inc. - Common Stock (NQ:MXCT)

1.630 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MaxCyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023 ↗

February 22, 2023

For those that want to take a journey on the wild side of the market, these penny stocks may offer significant upside rewards.

Via InvestorPlace

MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences

February 01, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

January 03, 2023

MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Earnings Perspective: Return On Capital Employed ↗

December 14, 2022

Via Benzinga

MaxCyte Expects Q1 Sales To Beat Expectations, CFO Resigns ↗

April 13, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

7 Hot Stocks to Book Profits In Before 2023 ↗

December 19, 2022

With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in.

Via InvestorPlace

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

December 05, 2022

Curamys to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology.

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Reports Third Quarter 2022 Financial Results

November 09, 2022

From MaxCyte, Inc

Via GlobeNewswire

Earnings Outlook For MaxCyte ↗

November 08, 2022

MaxCyte (NASDAQ:MXCT) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that MaxCyte will...

Via Benzinga

MaxCyte to Participate in Upcoming Investor Conferences

November 02, 2022

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

October 12, 2022

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders ↗

September 28, 2022

MaxCyte Inc (NASDAQ: MXCT) has signed a

Via Benzinga

MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

September 28, 2022

From MaxCyte, Inc

Via GlobeNewswire

Recap: MaxCyte Q2 Earnings ↗

August 10, 2022

MaxCyte (NASDAQ:MXCT) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings MaxCyte reported in-line EPS of...

Via Benzinga

A Preview Of MaxCyte's Earnings ↗

August 09, 2022

MaxCyte (NASDAQ:MXCT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that MaxCyte will...

Via Benzinga

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Earnings Scheduled For May 9, 2022 ↗

May 09, 2022

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

Via Benzinga

MaxCyte's Return On Capital Employed Insights ↗

March 23, 2022

Benzinga Pro data, MaxCyte (NASDAQ:MXCT) reported Q4 sales of $10.15 million. Earnings fell to a loss of $4.87 million, resulting in a 81.85% decrease from last quarter. MaxCyte...

Via Benzinga

Earnings Scheduled For March 22, 2022 ↗

March 22, 2022

Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is projected to report quarterly loss at $0.18 per share on revenue of $338.69 million. • HUYA (...

Via Benzinga

11 Health Care Stocks Moving In Monday's Intraday Session ↗

January 24, 2022

Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares rose 35.6% to $2.17 during Monday's regular session. The current volume of 5.6 million shares is 531.8% of Aridis...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 23, 2021

Gainers Pasithea Therapeutics (NASDAQ:KTTA

Via Benzinga

MaxCyte, Inc. (MXCT) Q3 2021 Earnings Call Transcript ↗

November 12, 2021

MXCT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

91 Biggest Movers From Yesterday ↗

November 12, 2021

Gainers NuZee, Inc. (NASDAQ: NUZE) shares jumped 164.5% to settle at $5.29 on Thursday. NuZee manufacturing partner, Cuvee Coffee, reported an expansion into select Walmart...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 11, 2021

Gainers Liquidia (NASDAQ:LQDA) stock inc...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 01, 2021

Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's pre-market session. The company's market cap stands at $27.1...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

November 01, 2021

Welcome back, investor! We're starting off the trading week with a breakdown of the biggest pre-market stock movers for Monday!

Via InvestorPlace

28 Stocks Moving In Friday's Mid-Day Session ↗

October 08, 2021

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 08, 2021

Gainers ChemoCentryx (NASDAQ:CCXI) shares rose 77.65% to $34.82 during Friday's pre-market session. The company's market cap stands at $2.4 billion. eFFECTOR...

Via Benzinga

18 Stocks Moving in Friday's Pre-Market Session ↗

October 08, 2021

Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.